Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity
Cardiotrophin-1 (CT-1) is a heart-targeting cytokine that has been reported to exert a variety of activities also in other organs such as the liver, adipose tissue, and atherosclerotic arteries. CT-1 has been shown to induce these effects via binding to a transmembrane receptor, comprising the leuka...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2013/370715 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850157564701966336 |
|---|---|
| author | Mohamed Asrih François Mach Alessandra Quercioli Franco Dallegri Fabrizio Montecucco |
| author_facet | Mohamed Asrih François Mach Alessandra Quercioli Franco Dallegri Fabrizio Montecucco |
| author_sort | Mohamed Asrih |
| collection | DOAJ |
| description | Cardiotrophin-1 (CT-1) is a heart-targeting cytokine that has been reported to exert a variety of activities also in other organs such as the liver, adipose tissue, and atherosclerotic arteries. CT-1 has been shown to induce these effects via binding to a transmembrane receptor, comprising the leukaemia inhibitory factor receptor (LIFRβ) subunit and the glycoprotein 130 (gp130, a common signal transducer). Both local and systemic concentrations of CT-1 have been shown to potentially play a critical role in obesity. For instance, CT-1 plasma concentrations have been shown to be increased in metabolic syndrome (a cluster disease including obesity) probably due to adipose tissue overexpression. Interestingly, treatment with exogenous CT-1 has been shown to improve lipid and glucose metabolism in animal models of obesity. These benefits might suggest a potential therapeutic role for CT-1. However, beyond its beneficial properties, CT-1 has been also shown to induce some adverse effects, such as cardiac hypertrophy and adipose tissue inflammation. Although scientific evidence is still needed, CT-1 might be considered as a potential example of damage/danger-associated molecular pattern (DAMP) in obesity-related cardiovascular diseases. In this narrative review, we aimed at discussing and updating evidence from basic research on the pathophysiological and potential therapeutic roles of CT-1 in obesity. |
| format | Article |
| id | doaj-art-2dac5d0b502a45d2a1df9429258a5989 |
| institution | OA Journals |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-2dac5d0b502a45d2a1df9429258a59892025-08-20T02:24:07ZengWileyMediators of Inflammation0962-93511466-18612013-01-01201310.1155/2013/370715370715Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in ObesityMohamed Asrih0François Mach1Alessandra Quercioli2Franco Dallegri3Fabrizio Montecucco4Division of Cardiology, Faculty of Medicine, University of Geneva and Geneva University Hospital, Foundation for Medical Researches, Avenue de la Roseraie 64, 1211 Geneva 4, SwitzerlandDivision of Cardiology, Faculty of Medicine, University of Geneva and Geneva University Hospital, Foundation for Medical Researches, Avenue de la Roseraie 64, 1211 Geneva 4, SwitzerlandDivision of Cardiology, Faculty of Medicine, University of Geneva and Geneva University Hospital, Foundation for Medical Researches, Avenue de la Roseraie 64, 1211 Geneva 4, SwitzerlandDepartment of Internal Medicine, First Clinic of Internal Medicine, University of Genoa, 6 Viale Benedetto XV, 16143 Genoa, ItalyDivision of Cardiology, Faculty of Medicine, University of Geneva and Geneva University Hospital, Foundation for Medical Researches, Avenue de la Roseraie 64, 1211 Geneva 4, SwitzerlandCardiotrophin-1 (CT-1) is a heart-targeting cytokine that has been reported to exert a variety of activities also in other organs such as the liver, adipose tissue, and atherosclerotic arteries. CT-1 has been shown to induce these effects via binding to a transmembrane receptor, comprising the leukaemia inhibitory factor receptor (LIFRβ) subunit and the glycoprotein 130 (gp130, a common signal transducer). Both local and systemic concentrations of CT-1 have been shown to potentially play a critical role in obesity. For instance, CT-1 plasma concentrations have been shown to be increased in metabolic syndrome (a cluster disease including obesity) probably due to adipose tissue overexpression. Interestingly, treatment with exogenous CT-1 has been shown to improve lipid and glucose metabolism in animal models of obesity. These benefits might suggest a potential therapeutic role for CT-1. However, beyond its beneficial properties, CT-1 has been also shown to induce some adverse effects, such as cardiac hypertrophy and adipose tissue inflammation. Although scientific evidence is still needed, CT-1 might be considered as a potential example of damage/danger-associated molecular pattern (DAMP) in obesity-related cardiovascular diseases. In this narrative review, we aimed at discussing and updating evidence from basic research on the pathophysiological and potential therapeutic roles of CT-1 in obesity.http://dx.doi.org/10.1155/2013/370715 |
| spellingShingle | Mohamed Asrih François Mach Alessandra Quercioli Franco Dallegri Fabrizio Montecucco Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity Mediators of Inflammation |
| title | Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity |
| title_full | Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity |
| title_fullStr | Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity |
| title_full_unstemmed | Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity |
| title_short | Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity |
| title_sort | update on the pathophysiological activities of the cardiac molecule cardiotrophin 1 in obesity |
| url | http://dx.doi.org/10.1155/2013/370715 |
| work_keys_str_mv | AT mohamedasrih updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity AT francoismach updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity AT alessandraquercioli updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity AT francodallegri updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity AT fabriziomontecucco updateonthepathophysiologicalactivitiesofthecardiacmoleculecardiotrophin1inobesity |